Interaction between lead and noradrenergic genotypes affects neurocognitive functions in attention-deficit/hyperactivity disorder: a case control study

CURRENT STATUS: UNDER REVIEW

BMC Psychiatry

Jae-Won Choi
Gyeongsang National University Hospital

ORCiD: https://orcid.org/0000-0002-4516-1954

A-Hyun Jung
Suyeong-gu Mental health Service

Sojeong Nam
University of Iowa

Kyoung Min Kim
Dankook University College of Medicine

Jun Won Kim
Catholic University of Daegu School of Medicine

Soo Yeon Kim
Pusan National University Hospital

Jae-Won Kim
Seoul National University College of Medicine

kimjw412@snu.ac.kr Corresponding Author

Bung-Nyun Kim
Seoul National University College of Medicine

kbn1@snu.ac.kr Corresponding Author

DOI:
10.21203/rs.3.rs-15822/v1

SUBJECT AREAS
Psychiatry
KEYWORDS
lead, neurocognitive performance, ADHD, dopamine, noradrenaline
Abstract

Background We aimed to evaluate neurocognitive functions associated with blood lead levels and their relationship with the interactions between lead and dopaminergic or noradrenergic genotypes in youths with attention-deficit/hyperactivity disorder (ADHD).

Methods A total of 267 youths with ADHD and 101 healthy controls (aged 5 to 18 years) participated in this study. A semi-structured interview, the Korean Kiddie Schedule for Affective Disorders and Schizophrenia–Present and Lifetime version (K-SADS-PL), was conducted for psychiatric diagnostic evaluation. Blood lead levels were measured, and their interaction with dopaminergic or noradrenergic genotypes for ADHD, namely dopamine transporter (DAT1), dopamine receptor D4 (DRD4), and alpha-2A-adrenergic receptor (ADRA2A) genotypes were investigated. All participants were assessed using the ADHD Rating Scale-IV (ADHD-RS). Participants also completed the continuous performance test (CPT) and Stroop Color-Word Test (SCWT). Analysis of covariance was used for comparison of blood lead levels between ADHD and control groups. A multivariable linear regression model was used to evaluate the associations of blood lead levels with the results of ADHD-RS, CPT, and SCWT; adjusted for intelligence quotient (IQ), age, and sex. Path analysis model was used to identify mediating effects of neurocognitive functions on blood lead levels and ADHD symptoms.

Results There was a significant difference in blood lead levels between the ADHD and control groups (1.4±0.5 vs. 1.3±0.5 µg/dL, p=0.004). Blood lead levels showed a positive correlation with scores on omission errors of CPT (r=0.16, p=0.01) and on the hyperactivity-impulsivity subscale of ADHD-RS (r=0.14, p=0.03). In the multivariable linear regression model, blood lead levels were associated with CPT omission errors (B=0.14, p=0.02). Regarding the effects of lead on ADHD symptoms, hyperactivity-impulsivity was mediated by omission errors of CPT. An interaction effect was detected between ADRA2A genotype and lead levels on omission errors (B=0.12, p=0.04).

Conclusions Our results indicate that neurocognitive functions at least partly mediate the association between blood lead levels and ADHD symptoms, and that neurocognitive functions are affected by the interaction between blood lead levels and noradrenergic genotype.
Background
Attention-deficit/hyperactivity disorder (ADHD) occurs in 5% of children [1] and is characterized by symptoms of hyperactivity, impulsivity, and inattention leading to functional impairments in social activities, performance at school, and family relationships [2]. Despite the complex etiology of ADHD, there is a general consensus that ADHD is underpinned by environmental and genetic factors [3][4]. Among psychiatric disorders, ADHD is considered a highly heritable disorder with an estimated genetic heritability of 0.77 [4]. Many candidate genes, including dopaminergic, serotonergic, and noradrenergic genes, are reported to be involved in the synthesis and function of these neurotransmitters [5][6]. However, no single gene has yet been identified as a risk factor for the development of ADHD because of small effect sizes or insufficient sample sizes [7]. Further, only a few candidate genes have been replicated in genome-wide studies. Notwithstanding this limitation of genetic studies, several genes of interest have been identified. Dopaminergic genes such as the dopamine transporter (DAT1) and dopamine D4 receptor (DRD4) are most commonly reported as having positive associations with ADHD [6]. Recent imaging studies have focused on these two genes [8]. Noradrenergic genes, such as the alpha-2A adrenergic receptor gene (ADRA2A), have been studied in the context of their relationship with symptoms and executive functions in ADHD [9][10]. Genetic risk factors alone cannot explain the course and development of ADHD [3][7]. Alongside genetic risk factors, environmental risk factors account for an estimated 10–40% of the variance of the disorder [11]. In previous studies, environmental risk factors such as lead, manganese, or polychlorinated biphenyls correlated with symptoms of inattention and hyperactivity [3][5]. However, genetic and environmental risk factors do not independently influence symptomatology of, and vulnerability to ADHD. While environmental risk factors can affect the expression of genetic factors, genetic factors can also increase the likelihood of exposure and susceptibility to environmental factors [7]. In this context, Gene–Environment (G-E) interactions can provide explanations for differential sensitivities of ADHD development [12]. Although the effects of G-E interactions on ADHD have been investigated [13], a limited number of studies have supported this hypothesis, or identified the specific functions or symptoms affected by G-E interactions. Indeed, the majority of previous
reports have not been replicated [14]. According to a recent hypothesis, abnormalities in fronto-subcortical pathways caused by G-E interactions may influence neuropsychological endophenotypes, which can be measured by neuropsychological tests such as the continuous performance test (CPT) and Stroop Color-Word Test (SCWT). These neuropsychological endophenotypes may be presented as ADHD symptoms [15].

Lead is a well-known neurotoxicant that can damage multiple organs [16] and interfere with neurocognitive development [17]. As the lead absorption rate is higher in children than in adults and can easily cross the blood-brain barrier [18], children are especially susceptible to lead toxicity. In addition, even at levels lower than 10 µg/dL, it has been reported that lead exposure is associated with reduced intelligence, impaired academic achievement, and executive functioning [19][20]. An association of clinical diagnosis and symptoms of ADHD with low lead levels has been reported [14][21]. One study suggested that blood lead level is more strongly associated with hyperactivity/impulsivity symptoms than inattention [21], but a recent meta-analysis indicated that both symptoms exhibit a similar relationship with lead exposure [22]. In studies on associations between lead exposure and genes, an interaction between lead exposure and the N-methyl-d-aspartate (NMDA) receptor gene was identified to affect memory [23][24]. In children lacking the DRD4-7 polymorphism, impaired executive functions were linked to increased lead levels [25]. ADRA2A MspI and DraI polymorphisms were reported as predictors of treatment responses in ADHD with blood lead [15]. However, since the effects of lead exposure on ADHD symptoms were mediated more by poor performance on the stop task measuring response inhibition [21], it is necessary to examine which genes, of those demonstrating interactions with lead exposure, are correlated with executive functions that could mediate the effects of blood lead on symptoms of ADHD.

In this study, we aimed to evaluate which executive functions mediated the effects of blood lead levels on ADHD symptoms and the specific genes interacting with lead that were correlated with executive functions affected by blood lead levels. Based on previous studies, we hypothesized that lead, as an environmental risk factor, would interact with dopamine-related genes, such as DAT1 and DRD4, and norepinephrine-related genes, such as ADRA2A, and that this interplay would affect
specific executive functions, such as inattention, impulsivity, and processing speed.

Methods

Participants

Data from 355 participants comprising 259 patients with ADHD and 96 controls (aged 5 to 18 years) were pooled from two studies conducted with the same protocol between August 2010 and February 2015 at the child and adolescent psychiatry outpatient clinic of our hospital. In total, 90 patients with ADHD and 33 controls were initially recruited from the first study; after excluding two patients with ADHD and eight controls with missing genetic or environmental data, 88 patients with ADHD and 25 controls were assessed. In the second study, 191 patients with ADHD and 78 controls were initially recruited; after excluding 20 patients with ADHD and seven controls with missing genetic or environmental data, 171 patients with ADHD and 71 controls were assessed. A board-certified child and adolescent psychiatrist performed a psychiatric diagnostic evaluation, consisting of the Korean Kiddie Schedule for Affective Disorders and Schizophrenia–Present and Lifetime version (K-SADS-PL), for each participant in both groups. The validity and reliability of the Korean version of the K-SADS-PL have been ascertained [26]. Exclusion criteria for ADHD and control groups were: a hereditary genetic disorder; intelligence quotient (IQ) < 70; current or past history of brain trauma, organic brain disorder, seizure, or any other neurological disorder; schizophrenia or any other childhood-onset psychotic disorder; autism spectrum disorder, communication disorder, or learning disorder; major depressive disorder or bipolar disorder; obsessive compulsive disorder; Tourette’s syndrome or a chronic motor/vocal tic disorder. Detailed information about the study was provided to the parents and participants, and written informed consent was obtained from parents before enrolling any participants in the study. Both study protocols were approved by the Institutional Review Board of Seoul National University Hospital.

Assessment of ADHD symptoms and neuropsychological functions

The Korean version of the ADHD Rating Scale-IV (ADHD-RS) was completed by the parents to assess the severity of ADHD symptoms [27]. The ADHD-RS consists of two subscales assessing symptoms related to inattention and hyperactivity/impulsivity. Attention and executive functions of participants
were measured using the computerized CPT and SCWT. In the CPT, four variables were recorded: (1) omission errors interpreted as indicators of inattention, (2) commission errors interpreted as indicators of impulsivity, (3) mean reaction time interpreted as indicators of processing speed, and (4) standard deviations of the response times interpreted as indicators of variability or consistency of attention. The validity and reliability of the Korean version of the computerized CPT have been well-established [28]. The SCWT has been used to assess the ability to inhibit or ignore interference of irrelevant stimuli and was standardized in Korean [29]. To assess cognitive function, the Korean Educational Development Institute’s Wechsler Intelligence Scales for Children (KEDI-WISC) [30] was administered.

**Measurement of blood lead**

From each child, 5 mL venous blood samples were collected in metal-free tubes for lead measurements. Matrix modifier reagent composed of Triton X-100 and ammonium hydrogen phosphate dibasic was used for dilution, and the atomic absorption spectrometer–graphite furnace (Analyst 800-Zeeman collection; PerkinElmer, Singapore) was used to assay lead concentrations. Using this method, the detection limit for lead was 0.058 μg/dL. The methods for the assay have been described previously [31].

**Genotyping**

For genotyping of dopamine-related genes, a Genomic DNA Extraction Kit (Bioneer, Korea) was used to extract genomic DNA from blood lymphocytes. The 40-base pair VNTR polymorphism, located in the 3′-UTR of DAT1 on chromosome 5p15.3, was genotyped using T7-5 Long (5′-TGT GTA GGG AAC GGC CTG AG-3’) and T7-3a Long (5′-CTT CCT GGA GGT CAC GCC TCA AGG-3’). The genotypes of the DAT1 variant were divided into 10/10, with 10, and without 10/10. The DRD4 exon III VNTR polymorphism comprised 2–10 variable repeat units (1 unit = 48 base pairs) and was generated using the oligonucleotide primers (5′-ACC ACC GGC AGG ACC CTC ATG GCC TTG CGC TC-3’ and 5′-CTT CCT ACC CTG CCC GCT CAT GCT CTA CTG G-3’). The genotypes of the DRD4 variant were divided into 4/4, with 4, and without 4/4. For genotyping of norepinephrine-related genes, G-DEX™ II Genomic DNA Extraction Kit (Intron, Korea) was used to extract genomic DNA from whole blood lymphocytes.
ADRA2A polymorphisms were generated using oligonucleotide primers (5′-ACG TTG GAT GTT CTC CCA AGA TCC AGC TTC and 5′-ACG TTG GAT GCC TGC TGG GAG TTG GCC AT for the ADRA2A MspI [rs1800544] polymorphism; 5′-ACG TTG GAT GCT AAT TCC CCT TCC ATT CCC and 5′-ACG TTG GAT GGT GTA TTA CAG CGG GG for the ADRA2A DraI [rs553668] polymorphism). The genotypes of the ADRA2A MspI variant were divided into C/C, G/C, and G/G; and those of the ADRA2A DraI variant were divided into C/C, C/T, and T/T. Detailed genotyping processes have been previously described [32].

**Statistical Analysis**

We compared the blood lead and urine cotinine levels between ADHD and control groups using independent-sample t-tests and analysis of covariance (ANCOVA). In the ANCOVA, age, sex, and IQ, which were significantly different between groups, were used as covariates. A Pearson correlation analysis was used to examine the correlation of blood lead level with ADHD symptoms and neuropsychological functions in all participants. To analyze neuropsychological functions and ADHD symptoms on a spectrum, we analyzed the data from all participants concurrently. Multiple linear regression analyses were used to examine the associations of blood lead level with neuropsychological functions. Regression analyses were performed using a set of covariates including age, sex, and IQ. A path model was used to estimate the significance of the mediating effect of neuropsychological functions on the effects of lead on ADHD symptoms. Path model analysis was performed using the AMOS version 19.0 statistical program (SPSS Inc., USA). To evaluate the effect of the interaction between blood lead and genes on neuropsychological functions, hierarchical regression analyses were performed. The outcome variable was CPT omission errors, and four genes (DAT1, DRD4, ADRA2A MspI, ADRA2A DraI) were analyzed. For each regression, age, sex, and IQ were entered in the first block; diagnosis (i.e., ADHD or control) was entered in the second block; genotypes and lead level were entered in the third block; interaction terms between diagnosis or genotypes and lead level (i.e., diagnosis ´ lead; DAT1 VNTR ´ lead; DRD4 VNTR ´ lead; ADRA2A MspI ´ lead; and ADRA2A DraI ´ lead) were entered in the fourth block; and interaction terms among diagnosis, genotypes, and lead level (i.e., diagnosis ´ DAT1 VNTR ´ lead; diagnosis ´ DRD4 VNTR ´ lead; diagnosis ´ ADRA2A MspI ´ lead; and diagnosis ´ ADRA2A DraI ´ lead) were entered in the fifth
block. All statistical analyses except the path analyses were performed using SPSS 22.0 (SPSS Inc., Chicago, IL, USA). Results were considered statistically significant at \( p < .05 \) (two-tailed).

**Results**

**Demographic and clinical characteristics of participants**

Table 1 shows the demographic and clinical characteristics, genotype frequencies, and environmental measures of 259 patients with ADHD and 96 controls. There were significant differences between the ADHD and control groups in mean age, male ratio, and IQ (all \( p \)-values < .001). All subscales of the ADHD rating scale in the ADHD group were higher than those in the control group (all \( p \)-values < .001). In CPT, omission error, commission error, and response time variability were higher in the ADHD group than in the control group. There was a significant difference in blood lead levels between the ADHD and control groups. However, after adjusting for age, sex, and IQ, there was no significant difference in blood lead levels between the ADHD and control groups (\( F = 1.705, R^2 = .070, p = .192 \)). No differences in any of the genotype frequencies were found between the ADHD and control groups.

**Correlation between lead and clinical characteristics**

Table 2 shows the correlations between lead levels and ADHD symptoms/neuropsychological functions. The inattention and hyperactivity/impulsivity subscales of ADHD-RS, and omission errors and response time variability in CPT, showed positive correlations with blood lead levels. Age showed a negative correlation with blood lead levels. In the multivariable linear regression model, blood lead levels were associated with CPT omission errors (\( B = 3.75, 95\% \) confidence interval \([0.09, 7.40], p = .045\)), after adjusting for age, sex, and IQ (Additional file 1). [Place Table 2 around here]

**Mediating effects of neuropsychological functions on effects of lead on ADHD symptoms**

Omission errors and response time variability modified the effects of lead on ADHD symptoms after adjusting for age and sex (Figure 1). Both inattention and hyperactivity/impulsivity symptoms of ADHD were affected by lead, which was mediated by omission errors and response time variability in CPT, after adjusting for age and sex. [Place Figure 1 around here]

**Association between genotypes, lead, and CPT scores**
As shown in Table 3, no significant interactions were observed between DRD4 VNTR and ADRA2A MspI genotypes, and blood lead levels in predicting CPT omission errors. Only the interaction between ADRA2A Dral genotype and blood lead level showed an association and medium effect size with CPT omission errors. DAT1 VNTR showed a trend for an association with omission error. No interaction between lead and genes was associated with response time variability. [Place Table 3 around here]

Discussion

This study compared blood lead levels in ADHD and control groups. We identified associations among blood lead levels, ADHD symptoms, and brain functions assessed by neuropsychological tests. We identified that a subset of genes, previously associated with ADHD, may impact brain functions through their interactions with lead. This study is the first to reveal that interactions between lead and particular genes affect brain functions mediating the effects of lead on ADHD symptoms. Previous studies have reported associations of blood lead levels with ADHD symptoms or certain cognitive functions. Controversy remains regarding which domain of ADHD symptoms is more affected by lead. Research on patients with ADHD reported associations with hyperactivity-impulsivity [21], and a study conducted with a community sample revealed associations with impulsivity [31]. However, another study from a community sample reported that both inattention and hyperactivity were associated with blood lead levels[33], and a recent meta-analysis reported that effect sizes of the associations with inattention and hyperactivity-impulsivity were not substantially different [22]. This study confirmed that both of these symptoms were associated with blood lead levels. Since these two symptoms were strongly correlated when using Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria, it may be difficult to test the hypothesis that blood lead levels have greater effects on either of the two symptoms [34]. Therefore, it is necessary to assess the effects of lead not only on symptoms identified in the diagnostic criteria, but also on measurable brain functions. The CPT is a neuropsychological test that has a strong correlation with clinical diagnoses and is considered a useful assessment tool for classifying patients [35]. In our study, omission errors and response time variability showed an association with lead, and these two domains completely mediated the effects of lead on ADHD symptoms. There is controversy regarding the associations
between lead levels and brain functions, as reports state that only commission errors (representing impulsivity) were positively associated with blood lead levels in a general population group[31], while other reports claim only a positive association for omission errors (reflecting inattention)[33]. In terms of mediator effect studies, one study hypothesized that blood lead would affect striatal-frontal circuitry and reported that response suppression and response time variability, related with this circuitry, partially mediated hyperactivity-impulsivity [21]. However, this study did not identify mediation effects of omission errors that are known to reflect inattention. Lead may damage dopaminergic pathways, which are associated with impulsivity, as well as cholinergic pathways, which are associated with attention [36]. Our study confirmed that omission errors were affected by blood lead levels, even after controlling for age, sex, and IQ. Further, this function was observed to mediate the effects of lead on both impulsivity and inattention. Therefore, our results suggest that the effects of lead on attention may affect both of these cardinal ADHD symptoms.

With regard to the etiology of ADHD, interactions between environment and genes have been reported [12][37]. Lead is recognized as an environmental factor [3], and its potential as a genetic liability has been proposed [21]. Recent studies in a general population group reported effects of low lead levels on cognitive and executive functions [31][33], emphasizing the need for a complex model that accounts not only for the direct effect of lead, but also other influences such as genetic susceptibility, for understanding the pathogenesis of ADHD. Our study confirmed that candidate ADHD genes, ADRA2A Dral and DAT1 (trend level), affected omission errors by interacting with lead. The alpha-2A-adrenergic receptor is involved in executive functions in the prefrontal cortex, such as working memory, attention, and impulse control. However, in a meta-analysis, the association between Dral polymorphisms and ADHD was not confirmed, as the odds ratio and p-value were .92 and .825, respectively [38]. To our knowledge, there have been no studies to date on the interactions between this gene and lead, although a recent study identified both the Dral polymorphism and blood lead level as factors predicting the therapeutic response to methylphenidate administration among patients with ADHD [15]. Results on the interactions between the Dral polymorphism and ADHD should be validated in future studies. Nevertheless, our study is the first to suggest several genes,
whose associations with ADHD have yet to be proven, that are associated with brain functions mediating ADHD symptoms through their interactions with lead.

Previous studies have reported that lead has effects on cognitive functions and associations with intelligence. While no significant association with intelligence was observed in the present study, recent studies reporting lower average lead levels were able to demonstrate an association [21]. Future studies should analyze the potential modifying effect of other factors such as socioeconomic status (a covariate in other studies), or parents’ education levels.

In the comparison of blood lead levels in the ADHD and control groups, significantly higher blood lead levels were observed in the ADHD group. However, after correcting for age, sex, and IQ, there was no significant difference. ANCOVA revealed that sex significantly affected differences in blood lead levels ($F = 14.147$, $R^2 = .070$, $p < .001$). In analyses of males and females separately, males did not show a significant difference in blood lead levels between the ADHD and control groups ($1.48 \mu g/dL$ vs. $1.42 \mu g/dL$, $p = .439$); however, in females, average blood lead levels in the ADHD group were significantly higher ($1.31 \mu g/dL$ vs. $1.09 \mu g/dL$, $p = .011$). Since the number of males in the ADHD group was greater than that of females, and the average blood lead levels were higher in males than in females overall, the average blood lead levels of the ADHD group were also higher than that of the control group. However, in females, it was confirmed that the average blood levels of the ADHD group were significantly higher than those of the control group. As previously reported, there was still a significant effect under $5 \mu g/dL$, which is the standard level per Centers for Disease Control and Prevention. In addition, although males did not exhibit differences in blood lead levels between the ADHD and control groups, there was a significant effect on symptoms, suggesting that ADHD pathogenesis is also affected by interactions with other factors such as the genes identified in this study.

Limitations And Strengths
First, this study was unable to balance the proportion of males and females and match for age and sex between the ADHD and control groups. This limitation was addressed by using age, sex, and IQ as covariates in the statistical comparisons. Moreover, this study recruited participants from a single
source, which may limit generalizability. Therefore, further multicenter studies should confirm the results. In addition, in diagnosing ADHD symptoms, the same symptoms are supposed to be identified in two different settings, but this study assessed symptoms from parents only. However, we increased the accuracy of diagnosis by using a structured assessment tool. Further, we did not classify participants by the presence of diagnosis in the analysis of associations between lead and symptoms. Instead, we considered a wide range of symptoms (from subclinical to clinical symptoms) for the statistical analyses. A strength of this study is that we attempted to understand the disorder across the spectrum based on changes in the DSM-5.

Conclusions
Blood lead levels influenced ADHD symptoms, including both inattention and hyperactivity-impulsivity, and the effects were mediated by omission errors and response time variability, as measured by CPT. Omission errors were affected by interactions between lead and the ADRA2A DraI gene. It is necessary to confirm whether these results are replicable through additional studies on interactions of lead with relevant genes.

Abbreviations
attention deficit hyperactivity disorder (ADHD)
continuous performance test (CPT)
dopamine transporter (DAT1)
dopamine D4 receptor (DRD4)
alpha-2A adrenergic receptor gene (ADRA2A)
Gene–Environment interactions (G-E)
continuous performance test (CPT)
Stroop Color-Word Test (SCWT)
N-methyl-d-aspartate (NMDA)
Korean Kiddie Schedule for Affective Disorders and Schizophrenia–Present and Lifetime version (K-SADS-PL)
intelligence quotient (IQ)
ADHD Rating Scale-IV (ADHD-RS)

Korean Educational Development Institute’s Wechsler Intelligence Scales for Children (KEDI-WISC) analysis of covariance (ANCOVA)

Diagnostic and Statistical Manual of Mental Disorders (DSM)

Declarations

Ethics approval and consent to participate:

Both study protocols were approved by the Institutional Review Board of Seoul National University Hospital. Written informed consent was obtained from parents, and sufficient explanation of the study prior to enrollment was provided to all parents and youths.

Consent for publication:

Not applicable

Availability of data and materials:

The datasets analysed during the current study are available from the corresponding author on reasonable request.

Competing interests:

The authors declare that they have no competing interests.

Funding:

This study was supported by the Promising-Pioneering Researcher Program through Seoul National University (SNU) in 2015 to J. W. Kim; the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2015M3C7A1028926 to B. N. Kim); and the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF-2015R1A2A2A01004501 to J. W. Kim). These funders had a role in the study design, collection of the data, analysis of the data, or writing of the manuscript.

Authors contributions:

JWK and BNK conceptualized the manuscript, helped conduct the statistical analysis and critically revised the manuscript based on feedback. JWC conducted with data analysis and drafted the initial manuscript. AHJ, SN, KMK, JWK and SYK helped conceptualize the manuscript, assisted with data
analysis and critically revised and review the manuscript. All authors read and approved the final manuscript.

Acknowledgements:

None.

References

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013

2. Rappley MD. Clinical practice. Attention deficit-hyperactivity disorder. N Eng J Med. 2005;13:165-73.

3. Banerjee TD, Middleton F, Faraone Environmental risk factors for attention-deficit hyperactivity disorder. Acta Paediatr. 2007;96:1269-74.

4. Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry. 2005;57:1215-20.

5. Ficks CA, Waldman ID. Gene-environment interactions in attention-deficit/hyperactivity disorder. Curr Psychiatry Rep. 2009;11:387-92.

6. Sharp SI, McQuillin A, Gurling HM. Genetics of attention-deficit hyperactivity disorder (ADHD). 2009;57:590-600.

7. Thapar A, Cooper M, Eyre O, Langley K. What have we learnt about the causes of ADHD? J Child Psychol Psychiatr. 2013;54:3-16.

8. Durston S. Imaging genetics in ADHD. 2010;53:832-8.

9. Waldman ID, Nigg JT, Gizer IR, Park L, Rappley MD, Friderici K. The adrenergic receptor α-2A gene (ADRA2A) and neuropsychological executive functions as putative endophenotypes for childhood ADHD. Cogn Affect Behav Neurosci. 2006;6:18-30

10. Wang B, Wang Y, Zhou R, Li J, Qian Q, Yang L, et al. Possible association of the alpha-2A adrenergic receptor gene (ADRA2A) with symptoms of
attention/deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 2006;141B:130-4.

11. Waldman ID, Rhee SH. Behavioral and molecular genetic studies of ADHD. In: Sandberg S, editor. Hyperactivity and attention disorders in childhood. New York: Cambridge University Press; 2002. p. 290-335.

12. Nigg J, Nikolas M, Burt SA. Measured gene-by-environment interaction in relation to attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2002;49:863-73.

13. Wermter AK, Laucht M, Schimmelmann BG, Banaschewski T, Sonuga-Barke EJ, Rietschel M, et al. From nature versus nurture, via nature and nurture, to gene x environment interaction in mental disorders. Eur Child Adolesc Psychiatry. 2010;19:199-210.

14. Kim S, Arora M, Fernandez C, Landero J, Caruso J, Chen A. Lead, mercury, and cadmium exposure and attention deficit hyperactivity disorder in children. Environ Res. 2013;126:105-10.

15. Kim JW, Sharma V, Ryan ND. Predicting methylphenidate response in ADHD using machine learning approaches. Int J Neuropsychopharmacol. 2015;10:18

16. Agency for Toxic Substances and Disease Registry (ATSDR). Atlanta, GA: [cited 2020 Jan 13]. U.S. Department of Health and Human Services, Public Health Service;[about 1 screen]. Available from: https://www.atsdr.cdc.gov/ToxProfiles/tp.asp?id=96&tid=22

17. Canfield RL, Kreher DA, Cornwell C, Henderson Low-level lead exposure, executive functioning, and learning in early childhood. Child Neuropsychol. 2003;9:35-53.

18. Costa LG, Aschner M, Vitalone A, Syversen T, Soldin Developmental neuropathology of environmental agents. Annu Rev Pharmacol Toxicol. 2004;44:87-110.
19. Canfield RL, Gendle MH, Cory-Slechta DA. Impaired neuropsychological functioning in lead-exposed children. Dev Neuropsychol. 2004;26:513-40.

20. Surkan PJ, Zhang A, Trachtenberg F, Daniel DB, McKinlay S, Bellinger DC. Neuropsychological function in children with blood lead levels <10 microg/dL. 2007;28:1170-77

21. Nigg JT, Knottnerus GM, Martel MM., Nikolas, M., Cavanagh, K., Karmaus, W, et al. Low blood lead levels associated with clinically diagnosed attention-deficit/hyperactivity disorder and mediated by weak cognitive control. Biol Psychiatry. 2008;63:325-31.

22. Goodlad JK, Marcus DK, Fulton Lead and attention-deficit/hyperactivity disorder (ADHD) symptoms: a meta-analysis. Clin Psychol Rev. 2013;33:417-25.

23. Guilarte TR, McGlothan Hippocampal NMDA receptor mRNA undergoes subunit specific changes during developmental lead exposure. Brain Res. 1998;790:98-107.

24. Lau WK, Yeung CW, Lui PW, Cheung LH, Poon NT, Yung KKL. Different trends in modulation of NMDAR1 and NMDAR2B gene expression in cultured cortical and hippocampal neurons after lead exposure. Brain Res. 2002;932:10-24.

25. Froehlich TE, Lanphear BP, Dietrich KN, Cory-Slechta DA, Wang N, Kahn RS. Interactive effects of a DRD4 polymorphism, lead, and sex on executive functions in children. Biol Psychiatry. 2007;62:243-9.

26. Kim YS, Cheon KA, Kim BN, Chang SA, Yoo HJ, Kim JW, et al. The reliability and validity of kiddie-schedule for affective disorders and schizophrenia-present and lifetime version-Korean version (K-SADS-PL-K). Yonsei Med J.2004;45:81-9.

27. So YK, Noh JS, Kim YS, Ko SG, Koh YJ. The reliability and validity of Korean parent and teacher ADHD Rating Scale. J Korean Neuropsychiatr Assoc. 2002;41:283-9.

28. Cho SZ, Chun SY, Hong KE, Shin MS. A study of the development and standardization
of ADHD diagnostic system. J Korean Acad Child and Adolesc Psychiatry. 2000;11:91-9.

29. Scarpina F, Tagini S. The Stroop Color and Word Test. Front Psychol. 2017;8:557.

30. Park KS, Yoon JR, Park HJ, Kwon KO. Korean educational developmental institute-Wechsler intelligence scale for children (KEDI-WISC). Seoul: Korean Educational Development Institute; 2002.

31. Hong SB, Im MH, Kim JW, Park EJ, Shin MS, Kim BN, et al. Environmental lead exposure and attention deficit/hyperactivity disorder symptom domains in a community sample of South Korean school-age children. Environ Health Perspect. 2015;123:271-6.

32. Park S, Kim BN, Cho SC, Kim Y, Kim JW, Lee JY, et al. Association between urine phthalate levels and poor attentional performance in children with attention-deficit hyperactivity disorder with evidence of dopamine gene-phthalate interaction. Int J Environ Res Public Health. 2014;11:6743-

33. Kim Y, Cho SC, Kim BN, Hong YC, Shin MS, Yoo HJ, et al. Association between blood lead levels (<5 mug/dL) and inattention-hyperactivity and neurocognitive profiles in school-aged Korean children. Sci Total Environ. 2010;408:5737-43.

34. Willcutt EG, Nigg JT, Pennington BF, Solanto MV, Rohde LA. Validity of DSM-IV attention deficit/hyperactivity disorder symptom dimensions and subtypes. J Abnorm Psychol. 2012;121:991-1010.

35. Ogundele MO, Ayyash HF, Banerjee S. Role of computerized continuous performance task tests in ADHD. Prog Neurol Psychiatry. 2011;15:8-13.

36. Cory-Slechta DA. Relationships between lead-induced learning impairments and changes in dopaminergic, cholinergic, and glutamatergic neurotransmitter system functions. Annu Rev Pharmacol Toxicol. 1995;35:391-415.
37. Tarver J, Daley D, Sayal K. Attention-deficit hyperactivity disorder (ADHD): an updated review of the essential facts. *Child Care Health* 2014;40:762-74

38. Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: a meta-analytic review. *Hum Genet.* 2009;126:51-90

Tables

**Table 1 Demographic Characteristics of Participants**

|                           | Patients (N = 259) | Controls (N = 96) | p (Effect size) |
|---------------------------|--------------------|-------------------|-----------------|
| Age, mean (SD) years      | 8.8 (2.4)          | 10.5 (3.0)        | < .001 (.63*)   |
| Male, n (%)               | 202 (78.0)         | 52 (54.2)         | < .001 (.51***) |
| IQ, mean (SD)             | 105.9 (14.5)       | 113.3 (16.4)      | < .001 (.48*)   |
| ADHD subtypes, n (%)      |                    |                   |                 |
| Combined                  | 73 (28.4)          |                   |                 |
| Inattentive               | 98 (38.1)          |                   |                 |
| Hyperactive-impulsive     | 57 (22.2)          |                   |                 |
| Not otherwise specified   | 29 (11.3)          |                   |                 |
| ADHD Rating Scale, mean (SD) |                |                   |                 |
| Inattention               | 15.0 (5.6)         | 3.6 (4.0)         | < .001 (2.76*)  |
| Hyperactivity-impulsivity | 10.2 (6.5)         | 1.7 (2.0)         | < .001 (2.02*)  |
| Total                     | 25.2 (10.7)        | 5.5 (5.7)         | < .001 (2.30*)  |
| Continuous Performance Test, mean (SD) |          |                   |                 |
| Omission errors           | 65.5 (20.4)        | 53.5 (15.1)       | < .001 (2.07*)  |
| Commission errors         | 65.5 (19.2)        | 55.5 (15.2)       | < .001 (2.58*)  |
| Response time             | 55.4 (12.1)        | 54.4 (13.2)       | .504 (.08*)     |
| Response time variability | 63.3 (17.9)        | 50.8 (15.4)       | < .001 (2.55*)  |
| Stroop Color-Word Test, mean (SD) |        |                   |                 |
| Word reading score        | 44.0 (11.6)        | 49.0 (9.5)        | < .001 (1.47*)  |
| Color naming score        | 45.4 (10.9)        | 50.9 (9.7)        | < .001 (2.53*)  |
| Color-Word score          | 45.3 (12.5)        | 50.3 (11.9)       | .001 (1.41*)    |
Interference score & 52.5 (11.3) & 49.1 (13.8) & .021 (.27*) \\
Environmental measure, mean (SD) & & & \\
Lead (µg/dL) & 1.4 (.5) & 1.3 (.5) & .005 (.20*) \\
Genotype & & & \\
DAT1, n (%) & & & \\
   With 10/10 & 217 (83.8) & 85 (88.5) & .525 (.15**) \\
   With 10 & 39 (15.1) & 10 (10.4) \\
   Without 10/10 & 3 (1.2) & 1 (1.0) \\
DRD4, n (%) & & & \\
   With 4/4 & 146 (56.4) & 58 (60.4) & .690 (.08**) \\
   With 4 & 99 (38.2) & 32 (33.3) \\
   Without 4/4 & 14 (5.4) & 6 (6.3) \\
ADRA2A Mspl, n (%) & & & \\
   C/C & 30 (11.6) & 12 (12.5) & .791 (.03**) \\
   G/C & 113 (43.6) & 38 (39.6) \\
   G/G & 116 (44.8) & 46 (47.9) \\
ADRA2A Dral, n (%) & & & \\
   C/C & 80 (30.9) & 23 (24.0) & .400 (.16**) \\
   C/T & 125 (48.3) & 53 (55.2) \\
   T/T & 54 (20.8) & 20 (20.8) \\

Note: *Cohen’s d values (.80=large, .50=medium, .20=small effect sizes).

**Cohen’s h values (.80=large, .50=medium, .20=small effect sizes).

ADHD, attention-deficit/hyperactivity disorder; IQ, intelligence quotient; SD, standard deviation

Table 2 Correlation Between Lead and Clinical Characteristics (N = 355)
|                          | $R$  | $p$ value |
|--------------------------|------|----------|
| Age                      | -.122| .022     |
| IQ                       | -.045| .403     |
| **Continuous Performance Test** |      |          |
| Omission errors           | .158 | .003     |
| Commission errors         | .055 | .304     |
| Response time             | .078 | .151     |
| Response time variability | .136 | .010     |
| **ADHD Rating Scale**     |      |          |
| Inattention               | .153 | .004     |
| Hyperactivity-impulsivity | .181 | .001     |
| Total                     | .173 | .002     |
| **Stroop Color-Word Test**|      |          |
| Word reading score        | -.078| .157     |
| Color naming score        | -.057| .298     |
| Color-Word score          | -.013| .815     |
| Interference score        | .062 | .272     |
Table 3 Associations Between Genotypes and Lead Interactions and CPT Scores (Omission Error and Response Time Variability) in the Multivariable Linear Regression Analysis

| Interaction          | Omission error |            | Response time variability |            |
|----------------------|----------------|------------|---------------------------|------------|
|                      | B    | 95% CI    | p         | Effect size | B    | 95% CI    |
| DAT1 X Lead          | 10.613 | -0.237,   | 0.055     | 0.274      | -0.198 | -10.527,  |
|                      |      | 21.463    |           |             |      | 10.132    |
| DRD4 X Lead          | -0.911 | -7.380,   | 0.782     | 0.253      | -4.065 | -10.166,  |
|                      |      | 5.558     |           |             |      | 2.036     |
| ADRA2A MspI X Lead   | 2.870 | -2.340,   | 0.279     | 0.262      | -1.588 | -6.526,   |
|                      |      | 8.079     |           |             |      | 3.350     |
| ADRA2A DraI X Lead   | 5.066 | 0.197,    | 0.041     | 0.269      | 3.392  | 8.173     |
|                      |      | 9.934     |           |             |      | 8.017     |

Note: †: adjusted for intelligence quotient, age, and sex.

Effect size: Cohen’s $f^2$
ADHD, attention-deficit/hyperactivity disorder; CI, confidence interval; CPT, continuous performance test; $B$, regression coefficient; $f^2$=Cohen’s $f^2$ values (.35=large, .15=medium, .02=small effect sizes)

**Supplemental Information Note**

**Additional file 1**

File name: Additional_file_1

File format: Word

Title of data: Table S1

Association between Blood Lead Concentration and Clinical Characteristics in the ADHD Group in the Multivariable Linear Regression Analysis

**Figures**

**Figure 1**

Cognitive control mediates blood lead effect on (ADHD) hyperactive-impulsive symptoms

(n=355, age and sex covaried)
Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

additional_file_1.docx